Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5427944 | 1.00 | PKM (0.46) | PKMKDM4ECYP4F2CYP4A11THRB | |
| Acetic Acid SCHEMBL6801309 | 1.00 | PKM (0.46) | PKMKDM4ECYP4F2CYP4A11THRB | |
| Acetic Acid SCHEMBL6681555 | 0.77 | PKM (0.42) | PKMKDM4ECYP4F2CYP4A11THRB | |
| Acetic Acid SCHEMBL6921925 | 0.77 | PKM (0.42) | PKMKDM4ECYP4F2CYP4A11THRB | |
| Acetic Acid SCHEMBL3872053 | 0.77 | PKM (0.42) | PKMKDM4ECYP4F2CYP4A11THRB | |
| Acetic Acid SCHEMBL2874562 | 0.75 | PKM (0.52) | PKMKDM4ECYP4F2CYP4A11THRB | |
| Acetic Acid SCHEMBL2815565 | 0.75 | PKM (0.52) | PKMKDM4ECYP4F2CYP4A11THRB | |
| Acetic Acid SCHEMBL9778642 | 0.75 | PKM (0.52) | PKMKDM4ECYP4F2CYP4A11THRB | |
| Acetic Acid SCHEMBL1627225 | 0.75 | PKM (0.52) | PKMKDM4ECYP4F2CYP4A11THRB | |
| Acetic Acid SCHEMBL1159570 | 0.74 | FFAR3 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024089159-A1 | MAIN PROTEASE INHIBITORS | UBIQ HOLDING B.V. (NL) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024055994-A1 | CRYSTAL FORM OF NAPHTHOFURAN-SUBSTITUTED GLUTARIMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南京明德新药研发有限公司 | 2024-03-21 | — | — | WO | disclosed |
| US-11874434-B2 | Ophthalmic devices comprising photochromic materials with reactive substituents | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2023-12-21 | — | — | US | disclosed |
| WO-2023234427-A1 | ANTIBODY-MULTIDRUG CONJUGATE PRECURSOR AND SYNTHETIC INTERMEDIATE THEREOF | ＵＢＥ株式会社 | 2023-12-07 | — | — | WO | disclosed |
| WO-2023234426-A1 | ANTIBODY-MULTIDRUG CONJUGATE | ＵＢＥ株式会社 | 2023-12-07 | — | — | WO | disclosed |
| EP-3125949-B1 | DENDRONIZED METALLIC OXIDE NANOPARTICLES, A PROCESS FOR PREPARING THE SAME AND THEIR USES | CENTRE NAT RECH SCIENT (FR) | 2023-11-08 | — | — | EP | disclosed |
| EP-4227307-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | Genzyme Corporation (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023114954-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2023-06-22 | — | — | WO | disclosed |
| CN-116139138-A | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-5147878-A | Hypotensive, antiarrhythmia agents | SANOFI (FR) | 1992-09-15 | — | — | US | disclosed |
| US-5039700-A | Cardiovascular disorders, antitumor agents | SANOFI (FR) | 1991-08-13 | — | — | US | disclosed |
| US-5037827-A | Useful for treatment of disease caused by platelet activating factory | EISAI CO., LTD. (JP) | 1991-08-06 | — | — | US | disclosed |
| US-5028710-A | Oxidation of corresponding 3-phenylthio indolizine | SANOFI (FR) | 1991-07-02 | — | — | US | disclosed |
| US-5017579-A | Use of aminoalkoxyphenyl derivatives for reducing and/or controlling excessive intraocular pressure | SANOFI (FR) | 1991-05-21 | — | — | US | disclosed |
| US-4994474-A | Hypotensive agents | SANOFI (FR) | 1991-02-19 | — | — | US | disclosed |
| US-4959385-A | MUSCLE RELAXANTS | MAY & BAKER LIMITED (GB) | 1990-09-25 | — | — | US | disclosed |
| EP-0353474-A2 | Glycerin derivative and its pharmacological use | Eisai Co., Ltd. (JP) | 1990-02-07 | — | — | EP | disclosed |
| CN-1039414-A | Glycerol derivatives and pharmaceutical use thereof | EISAI CO LTD (JP) | 1990-02-07 | — | — | CN | disclosed |
| US-4707497-A | DIETETICS | SANOFI (FR) | 1987-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | PKM 1001/4885KDM4E 1717/4885CYP4F2 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.